A previous study revealed that PMEPA1 isoforms (a, b, and d) may be a surrogate for androgen and TGF-β signaling in prostate cancer to serve as a biomarker for monitoring disease progression and aggressive clinical outcomes (3, 4). Here, PMEPA1 is linked to prostate carcinoma.